Key result
Apixaban 2.5 mg and 5 mg twice daily reduced all-cause hospitalisations versus placebo (HR 0.64, 95% CI 0.43-0.95 and HR 0.54, 95% CI 0.36-0.82, respectively).
Why the study?
Does extended anticoagulation with apixaban reduce all-cause hospitalisations in patients with venous thromboembolism?
RCT
Does extended anticoagulation with apixaban reduce all-cause hospitalisations in patients with venous thromboembolism?
Hazard Ratio: 0.64 (95% CI 0.43–0.95)
p-value: p=0.026
Extended anticoagulation with apixaban (2.5 mg or 5 mg twice daily) significantly reduces the rate of all-cause hospitalizations and prolongs the time to first hospitalization in patients with VTE.
No takes yet. Share an insight, caveat, or question.
Supports extended apixaban in VTE to reduce hospitalizations; extends prior recurrence-focused RCTs to patient-centered outcomes.
Liu et al. (2015) conducted an RCT in Venous thromboembolism. Apixaban vs. Placebo was evaluated on Rate of all-cause hospitalisations (HR 0.64, 95% CI 0.43-0.95, p=0.026). Apixaban 2.5 mg and 5 mg twice daily reduced all-cause hospitalisations versus placebo (HR 0.64, 95% CI 0.43-0.95 and HR 0.54, 95% CI 0.36-0.82, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: